

Daftar Pustaka

1. Guerrant RL, Van Gilder T, Steiner T, Thielman NM, Slutsker L, Tauxe RV, et al. Practice guidelines for the management of infectious diarrhea. *Clinical infectious diseases*. 2001;32:331-50.
2. Bhutta ZA. Acute gastroenteritis in children. In: Kliegman RM, Stanton BF, Schor NF, Geme JW, Behrman RE. *Nelson textbook of pediatrics*. 19th ed. 2011. Philadelphia. Elsevier Saunders. Pp:1323-38.
3. Chow CM, Leung AK, Hon KL. Acute gastroenteritis: from guidelines to real life. *Clinical and experimental gastroenterology*. 2010;3:97-112.
4. Prasetyo D, Martiza I, Soenarto Y. Surveillance of Rotavirus diarrhea in Hasan Sadikin Hospital Bandung. *MKB*. 2010;42(4):155-60.
5. Departemen Kesehatan RI. Direktorat Jendral Pemberantasan Penyakit Menular dan Penyehatan Lingkungan Pemukiman. *Buku ajar diare*. Jakarta: Departemen Kesehatan RI;1999.
6. Subagyo B, Santoso NB. Diare akut. Dalam: Juffrie M, Soenarto SSY, Oswari H, Arief S, Rosalina I, Mulyani NS. *Buku ajar gastroenterology-hepatologi*, jilid 1. 2010. Jakarta. UKK Gastroenterologi-Hepatologi IDAI.pp:87-120.
7. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhea: randomized double-blind placebo-controlled trial. *Lancet*. 2006;368:124-129.
8. Ward RL, Bernstein DI, Staat MA. Rotaviruses. In: Feigin RD, Cherry JD, Dammler-Harrison GJ, Kaplan SL. *Textbook of pediatric infectious diseases*, 6th ed. Philadelphia: 2009. Elsevier. pp:2245-70.
9. Committee on infectious diseases. Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. *Pediatrics*. 2007;119:171-181.
10. Favenec L, Ortiz J, Gargala G, Chegne NL, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adult and children from northern Peru. *Aliment Pharmacol Ther*. 2003;17:265-270.
11. Uchida R, Pandey BD, Sherchand JB, Ahmed K, Yokoo M, Nakagomi T, et al. Molecular epidemiology of rotavirus diarrhea among children and adults in Nepal: Detection of G12 strain with P[6] or P[8] and G11P[25] strain. *Journal of Clinical Microbiology*. 2006;44:3499-3505.
12. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for treatment of acute diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. *International journal of infectious diseases*. 2009;13: 518-523.
13. Rossignol JF, Gohary ME. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo controlled clinical trial. *Aliment pharmacol ther*. 2006;24:1423-1430.

14. Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. *Antimicrobial agents and chemotherapy*. 2006;50:1112-1117.
15. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of *Helicobacter pylori*, Selected anaerobic bacteria and parasites, and *Campylobacter jejuni*. *Antimicrobial agents and chemotherapy*. 2007;51:868-876.
16. Koletzko S, Osterrieder S. Acute infectious diarrhea in children. *Dtsch Arztebl Int*. 2009;106:539-48.
17. Elliot EJ. Acute gastroenteritis in children. *BMJ*. 2007;334:35-40.
18. Guandalini S. Acute diarrhea. In: Walker, Goutlet, Klienmann, eds. *Pediatrics gastrointestinal diseases* 4th ed.
19. Rossignol JF. Infectious diarrhea-etiology, diagnosis, and treatment. *US gastroenterology review* 2007;76-80.
20. Casburn-Jones AC, Farthing MJ. Management of infectious diarrhea. *Gut* 2004;53:296-305.
21. Surendran S. rotavirus infection: molecular changes and patophysiology. *EXCLI journal* 2008;7:154-62.
22. Suguna K, Rao CD. Rotavirus nonstructural proteins: a structural perspective. *Current science* 2010;98:352-359.
23. Tchouaffi-Nana F, Ballard TE, Cary CH, Macdonald TL, Sifri CD, Hoffman PS. Nitazoxanide inhibits biofilm formation by *Staphylococcus epidermidis* by blocking accumulation on surfaces. *Antimicrobial agents and chemotherapy* 2010;54:2767-2774.
24. Morris AP, Estes MK. Pathological consequences of rotavirus infection and its enterotoxin. *Am J Physiol Gastrointest Liver Physiol* 2001;281:303-310.
25. Gupta S, Tandon VR, Sharma SD, Gupta R, Gupta RK. Nitazoxanide: broad spectrum anti-protozoal. *JK science* 2006;8:60-61.
26. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. *Clinical infectious diseases* 2005;40:1173-1180.
27. Halsey J. Current approaches to the treatment of gastrointestinal infections: focus on nitazoxanide. *Clinical medicine: Therapeutics* 2009;1:263-275.
28. Schiff D, Barton LL. Nitazoxanide for rotavirus diarrhea, a preliminary trial. *AAP grand rounds* 2006;16:53.
29. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of *Giardia intestinalis*, *Entamoeba histolytica* and *Trichomonas vaginalis*. *Journal of antimicrobial chemotherapy* 2002;49:103-111.
30. Lynch M, Shieh W, Tatti K, Gentsch JR, Herris TF, Jiang B, et al. The pathology of rotavirus-associated deaths, using new molecular diagnostics. *Clinical infectious diseases*. 2003;37:1327-1333.

31. Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated with nitazoxanide. *Journal of infection* 2011;63:394-7.
32. Altindis M, Yavru S, Sinsek A, Ozkul A, Ceri A, Koc H. Rotavirus infection in children with acute diarrhea as detected by Latex agglutination, ELISA and Polyacrylamide gel electrophoresis. *Indian pediatrics*;2004;41:590-594.
33. Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in *Helicobacter pylori*. *Antimicrobial agents and chemotherapy*, 2002;46:2116-2123.
34. Rollo EE, Kumar P, Reich NC, Cohen J, Angel J, Greenberg HB, et al. The Epithelial cell response to Rotavirus infection. *J Immunol* 1999;163:4442-4452.
35. Esposito M, Stettler R, Moores SL, Pidathala C, Muller N, Stachulski A, et al. In vitro efficacies of nitazoxanide and other thiazolides against *Neospora caninum* Tachyzoites reveal antiparasitic activity independent of the nitro group. *Antimicrobial agents and chemotherapy*, 2005;49:3715-3723.
36. Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. *Expert opin investing drugs* 2010;19(2): 215-34.
37. Blutt SE, Conner ME. The gastrointestinal frontier: IgA and virus. *Frontiers in immunology*. 2013;4:1-12.
38. Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. *Nature* 2010;8:656-65.
39. Kheirouri S, Alizadeh M. Decreased serum and mucosa immunoglobulin A levels in vitamin A- and zinc-deficient mice. *Central European journal of immunology* 2014;39:165-9.
40. Dion C, Montage P, Bene MC, Faure G. Measurement of faecal immunoglobulin A levels in young children. *Journal of Clinical Laboratory Analysis*. 2004;18:195-9.
41. Baratawidjaya KG. *Imunologi dasar*. 7ed. Jakarta: Balai penerbit FKUI. 2006.
42. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nature reviews*. 2014;14:141-53.
43. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. *Immunology*. 2011;4:603-10.
44. Rollo EE, Kumar P, Reich NC, Cohen J, Angel J, Greenberg HB, et al. The Epithelial cell response to Rotavirus infection. *J Immunol* 1999;163:4442-4452.
45. Romark Laboratories, L. C. *Alinia Prescribing information*. Tampa, FL, USA 2005.
46. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front line body defences. *Nature*. 2003;3:63-72.
47. Kane EM, Turcois RM, Arvay ML, Garcia S, Bresee JS, Glass RI. The epidemiology of rotavirus diarrhea in Latin America. Anticipating rotavirus vaccine. *Pan Am J Public Health* 2004;16:371-377.

48. Desselberger U, Manktelow E, Li W, Cheung W, Iturriza-Gomara M, Gray J. Rotaviruses and rotavirus vaccines. *British medical bulletin* 2009;90:37-51.
49. Anderson VR, Curran MP. Nitazoxanide; A review of its use in the treatment of gastrointestinal infections. *Drugs* 2007;67:1947-67.
50. Rodriguez L, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory infections in children: A public health problem. *International Journal of Environmental Research and Public Health*. 2011;8:1174-1205.
51. McLeod C, Morris PS, Snelling TL, Carapetis JR, Bowen AC. Nitazoxanide for the treatment of infectious diarrhea in the Northern Territory, Australia 2007-2012. *Rural and Remote Health*. 2013;1-8.
52. Aslam S, Musher DM. Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. *Future Microbiol.* 2007;6:583-90.
53. Amadi B, Mwiya M, Musuku J. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. *Lancet*. 2002;360:1375-80.
54. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by *Cryptosporidium parvum*: A prospective, randomized, double-blind, placebo-controlled study of nitazoxanide. *Journal of Infectious Diseases*. 2001;184:103-6.
55. Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. *Am. J. Trop. Med. Hyg.* 2003;68:384-5.
56. Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of *Clostridium difficile* colitis. *Clin. Infect. Dis.* 2006;43:421-427.
57. Cohen SA. Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective. *Current Medical Research and Opinion*. 2005;21:999-1004.

